Home Search

ctxr - search results

If you're not happy with the results, please do another search

Citius (CTXR) CEO Myron Holubiak Live on TV, 1:20 Today, June 30th.

VIDEO: Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
Citius Pharma

Citius Pharma (CTXR) On The Move.

One Of Our Top 5 Biotech Picks For 2020 Up 23% Yesterday, Indicating Up Another 24% This Morning. Inquiring Minds Want...

Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...

Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).   Citius Announces Pre-IND Submission to FDA Under the Coronavirus...
Biotech Stock Review, Novellus, Citius

Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19

New Report: Citius (CTXR) Trades 13 Million Shares on CoronaVirus and Candida Auris News.

Announces Mino-lok® Erdicates the Deadly and Untreatable C. Auris Bacteria.Announces License of Treatment for CoronaVirus Respiratory Failure.

VirnetX (VHC) Scores $440 Million and Citius Pharma (CTXR) Sees Market Expand to Over...

Internet Stock Review Blast from the past scores big! We added VirnetX (VHC)...
Citius, Biotech Stock Review

Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

PHASE III PROGRESS October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019...

Okay, so What’s Next for Citius Pharma (CTXR) $1.16?

Dawson James Broker/Dealer Updates. Price Target Remains at $7.00. "OK, So what’s Next? Topline data from the superior efficacy...
Citius Pharma

Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.

STREET INSIDER H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals...
Citius Pharmaceutical, CTXR, Biotech Stock Review

New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...

Latest article

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

GeoVax (GOVX) Launches Vaccine Manufacturing System.

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...

Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody...